First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Submitted by admin on August 22, 2024 - 11:15am
Source: 
Biopharma Reporter
News Tags: 
ImmPACT Bio
CAR-T
MS
multiple sclerosis
FDA
clinical trials
Headline: 
First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1
snippet: 

ImmPACT Bio has received FDA clearance to start clinical trials for its CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis (MS) patients.

Do Not Allow Advertisers to Use My Personal information